Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting CD157 in AML using a novel, Fc-engineered antibody construct.

Christina Krupka1,2,3, Felix S Lichtenegger1,2,3, Thomas Köhnke1,2,3

  • 1Department of Internal Medicine III, Klinikum of The LMU Munich, Munich, Germany.

Oncotarget
|April 19, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal of hematology & oncology·2026
Same author

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same author

The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis.

Intensive care medicine·2026
Same author

Prognostic impact of t(9;11) and del(7q) as intermediate-risk abnormalities in acute myeloid leukemia following allo-transplant: an Acute Leukemia Working Party study from the European Society for Blood and Marrow Transplantation.

Haematologica·2026
Same author

Sequence-encoded differences in the conformational ensembles of CITED transcriptional activation domains impact coactivator binding.

Protein science : a publication of the Protein Society·2026
Same author

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

JAMA oncology·2026

A novel antibody targeting CD157, MEN1112, shows promise for treating acute myeloid leukemia (AML). This engineered antibody effectively triggers natural killer cells to kill AML cells, including leukemia-initiating cells.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Antibody-based immunotherapy is a key strategy for treating acute myeloid leukemia (AML).
  • Chemorefractory leukemic cells pose a significant challenge in AML treatment.
  • CD157 is a potential target for novel immunotherapies.

Purpose of the Study:

  • To evaluate the efficacy of a novel Fc-engineered antibody, MEN1112, targeting CD157 for AML immunotherapy.
  • To assess CD157 expression levels in AML patient samples and leukemia-initiating cells.
  • To investigate the mechanism of action of MEN1112, including natural killer (NK) cell-mediated cytotoxicity.

Main Methods:

  • Expression analysis of CD157 in primary AML samples and healthy bone marrow.
  • Ex vivo assessment of MEN1112-induced cytotoxicity against AML cell lines and primary cells using NK cells.
Keywords:
AMLAntibodyCD157Fc-engineeringImmunotherapy

Related Experiment Videos

  • Comparison of Fc-engineered MEN1112 with its parental analogue.

    • Main Results:

    • CD157 is highly expressed in 97% of primary AML samples and on leukemia-initiating cells.
    • MEN1112 demonstrated significant NK cell-mediated cytotoxicity against AML cells.
    • Fc-engineering enhanced antibody-dependent cellular cytotoxicity (ADCC) compared to the parental antibody.
    • Cytotoxicity varied among AML patients due to intrinsic NK cell defects.

    Conclusions:

    • CD157 is a relevant target for AML immunotherapy.
    • MEN1112 is a promising therapeutic candidate for AML, warranting further clinical investigation.
    • Patient-specific NK cell function and potential combinatorial strategies may influence treatment outcomes.